Merck’s (MRK) WINREVAIR Shows Strong Results in HYPERION Trial

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared encouraging results from its Phase 3 HYPERION trial. The study tested a drug called WINREVAIR (sotatercept-csrk) against a placebo, both combined with standard treatment, in adults recently diagnosed with pulmonary arterial hypertension (PAH)—a serious lung condition.

Merck’s (MRK) WINREVAIR Shows Strong Results in HYPERION Trial

A lab technician in a biopharmaceutical laboratory, surrounded by technology and equipment necessary for advanced research.

The trial involved around 320 people from different countries. Most participants were already on two background treatments, unlike earlier trials where most were on three. WINREVAIR showed it could significantly slow down the worsening of PAH compared to the placebo. However, the company didn’t release the exact numbers yet, only saying the results were both statistically and medically meaningful.

Merck & Co., Inc. (NYSE:MRK) is a global biopharmaceutical company. It discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products. Its key products include Keytruda (cancer), Gardasil (HPV vaccine), Januvia (diabetes), and Bridion (anesthesia reversal).

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Value Penny Stocks to Buy According to Analysts and 12 Best Augmented Reality Stocks to Buy According to Analysts.

Disclosure: None.